LV10930B - Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen - Google Patents

Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen Download PDF

Info

Publication number
LV10930B
LV10930B LVP-95-77A LV950077A LV10930B LV 10930 B LV10930 B LV 10930B LV 950077 A LV950077 A LV 950077A LV 10930 B LV10930 B LV 10930B
Authority
LV
Latvia
Prior art keywords
weight
parts
matrix
pyrrolidone
component
Prior art date
Application number
LVP-95-77A
Other languages
English (en)
Latvian (lv)
Other versions
LV10930A (lv
Inventor
Eric Teillaud
Antoine Sawaya
Marie-Christine Math
Original Assignee
Lhd Lab Hygiene Dietetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lhd Lab Hygiene Dietetique filed Critical Lhd Lab Hygiene Dietetique
Publication of LV10930A publication Critical patent/LV10930A/xx
Publication of LV10930B publication Critical patent/LV10930B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
LVP-95-77A 1994-03-28 1995-03-21 Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen LV10930B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403598A FR2717688B1 (fr) 1994-03-28 1994-03-28 Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.

Publications (2)

Publication Number Publication Date
LV10930A LV10930A (lv) 1995-12-20
LV10930B true LV10930B (en) 1996-08-20

Family

ID=9461478

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-77A LV10930B (en) 1994-03-28 1995-03-21 Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen

Country Status (23)

Country Link
US (1) US5605702A (de)
EP (1) EP0674900B1 (de)
JP (1) JPH07309762A (de)
KR (1) KR950031056A (de)
CN (1) CN1114587A (de)
AT (1) ATE173617T1 (de)
AU (1) AU684601B2 (de)
CA (1) CA2145579A1 (de)
CZ (1) CZ289211B6 (de)
DE (1) DE69506156T2 (de)
DK (1) DK0674900T3 (de)
ES (1) ES2127484T3 (de)
FI (1) FI951425A (de)
FR (1) FR2717688B1 (de)
GR (1) GR3029402T3 (de)
HU (1) HU219245B (de)
LV (1) LV10930B (de)
NO (1) NO308124B1 (de)
NZ (1) NZ270810A (de)
PL (1) PL179022B1 (de)
RU (1) RU2144818C1 (de)
SK (1) SK281234B6 (de)
ZA (1) ZA952468B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2081823T3 (es) * 1988-10-27 1996-03-16 Schering Ag Agente para la aplicacion transdermica, que contiene gestoden.
KR970706805A (ko) * 1994-11-18 1997-12-01 나까토미 히로타카 경피흡수첩부제(percutaneously absorbable patch)
FR2739032B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
BR9710682A (pt) 1996-05-24 1999-08-17 Angiotech Pharm Inc Composi-{es e m-todos para tratar ou prevenir doen-as das vias do organismo
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
DE10118282A1 (de) * 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
ATE461681T1 (de) * 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP3025722B1 (de) 2003-10-03 2020-05-27 Thorn BioScience, LLC Verfahren zur synchronisierung der ovulation für zeitlich angepasstes brüten ohne hitzenachweis
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
DK2421545T3 (en) 2009-04-23 2018-03-12 Jbs United Animal Health Ii Llc PROCEDURE AND COMPOSITION TO SYNCHRONIZE THE TIME OF INSEMINATION.
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CN104994865A (zh) 2012-11-28 2015-10-21 杰碧斯联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2970408B1 (de) 2013-03-12 2018-01-10 Amgen Inc. Hochwirksame und selektive inhibitoren von nav1.7
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
FR2612785A1 (fr) * 1987-03-25 1988-09-30 Lhd Lab Hygiene Dietetique Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5032402A (en) * 1988-10-27 1991-07-16 The University Of Kentucky Research Foundation 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer
KR900701242A (ko) * 1988-12-01 1990-12-01 스타이너 브이. 캔스타드 에스트라디올의 경피전달용 조성물
US5248676A (en) * 1990-05-17 1993-09-28 Hisamitsu Pharmaceutical Co., Inc. Estradiol percutaneous administration preparations

Also Published As

Publication number Publication date
FR2717688B1 (fr) 1996-07-05
ZA952468B (en) 1995-12-19
AU1497995A (en) 1995-10-05
DE69506156D1 (de) 1999-01-07
DK0674900T3 (da) 1999-06-23
ATE173617T1 (de) 1998-12-15
AU684601B2 (en) 1997-12-18
JPH07309762A (ja) 1995-11-28
SK281234B6 (sk) 2001-01-18
FI951425A (fi) 1995-09-29
DE69506156T2 (de) 1999-07-22
EP0674900A1 (de) 1995-10-04
KR950031056A (ko) 1995-12-18
HU219245B (en) 2001-03-28
CZ289211B6 (cs) 2001-12-12
HUT75237A (en) 1997-05-28
SK39195A3 (en) 1995-10-11
NO308124B1 (no) 2000-07-31
NO951125D0 (no) 1995-03-24
NO951125L (no) 1995-09-29
GR3029402T3 (en) 1999-05-28
CZ76895A3 (en) 1995-10-18
LV10930A (lv) 1995-12-20
CA2145579A1 (en) 1995-09-29
FI951425A0 (fi) 1995-03-24
NZ270810A (en) 1996-05-28
PL179022B1 (en) 2000-07-31
ES2127484T3 (es) 1999-04-16
PL307889A1 (en) 1995-10-02
FR2717688A1 (fr) 1995-09-29
HU9500881D0 (en) 1995-05-29
RU2144818C1 (ru) 2000-01-27
CN1114587A (zh) 1996-01-10
US5605702A (en) 1997-02-25
EP0674900B1 (de) 1998-11-25

Similar Documents

Publication Publication Date Title
US5605702A (en) Eva-based transdermal matrix system for the administration of an estrogen and/or a progestogen
US5580572A (en) Styrene-isoprene-styrene copolymer-based transdermal matrix system for the administration of an oestrogen and/or a progestogen
US6007835A (en) Transdermal matrix system
AU702542B2 (en) Transdermal matrix system
US5783208A (en) Transdermal drug delivery matrix for coadministering estradiol and another steroid
RU2140784C1 (ru) Содержащая эстрадиол трансдермальная терапевтическая система
RU95104224A (ru) Самоклеющаяся трансдермальная матричная система на основе этиленвинилацетата для введения в организм эстогена и/или прогестогена и способы ее получения
US5919477A (en) Transdermal system for simultaneous delivery of a number of active principles
MXPA98002327A (en) Transderm matrix system
AU628866B2 (en) A percutaneous pharmaceutical preparation
MXPA97004527A (en) Transdermic system of administration simultaneade various principles acti